Protein expression overlap: more important than which proteins change in expression?

References

• Arendt T. Alzheimer’s disease as a disorder of dynamic brain self-organization. Prog. Brain Res.147, 355–378 (2005).
   PubMedGoogle Scholar
• Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteomics4(12), 3943–3952 (2004).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Gnjec A, Poon HF et al. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer’s disease: an initial assessment. J. Alzheimers Dis.10(4), 391–397 (2006).
   PubMed Web of Science ®Google Scholar
• Castegna A, Aksenov M, Aksenova M et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med.33(4), 562–571 (2002).
   PubMed Web of Science ®Google Scholar
• Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J. Neurochem.85(6), 1394–1401 (2003).
   PubMed Web of Science ®Google Scholar
• Celis JE, Moreira JM, Cabezon T et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell. Proteomics4(4), 492–522 (2005).
   PubMed Web of Science ®Google Scholar
• Celis JE, Moreira JM, Gromova I et al. Towards discovery-driven translational research in breast cancer. FEBS J.272(1), 2–15 (2005).
   PubMed Web of Science ®Google Scholar
• David DC, Ittner LM, Gehrig P et al. β-amyloid treatment of two complementary P301L tau-expressing Alzheimer’s disease models reveals similar deregulated cellular processes. Proteomics6(24), 6566–6577 (2006).
   PubMedGoogle Scholar
• Di Poto C, Iadarola P, Bardoni AM et al. 2-DE and MALDI-TOF-MS for a comparative analysis of proteins expressed in different cellular models of amyotrophic lateral sclerosis. Electrophoresis28(23), 4320–4329 (2007).
   PubMed Web of Science ®Google Scholar
• Diedrich M, Mao L, Bernreuther C et al. Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice. Proteomics8(6),1266–1275 (2008).
   PubMed Web of Science ®Google Scholar
• Leverenz JB, Umar I, Wang Q et al. Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol.17(2), 139–145 (2007).
   PubMed Web of Science ®Google Scholar
• Periquet M, Corti O, Jacquier S, Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J. Neurochem.95(5), 1259–1276 (2005).
   PubMed Web of Science ®Google Scholar
• Perluigi M, Poon HF, Maragos W et al. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol. Cell. Proteomics4(12), 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Sultana R, Boyd-Kimball D, Cai J et al. Proteomics analysis of the Alzheimer’s disease hippocampal proteome. J. Alzheimers Dis.11(2), 153–164 (2007).
   PubMedGoogle Scholar
• Tsuji T, Shiozaki A, Kohno R, Yoshizato K, Shimohama S. Proteomic profiling and neurodegeneration in Alzheimer’s disease. Neurochem. Res.27(10), 1245–1253 (2002).
   PubMedGoogle Scholar
• Wilson KE, Marouga R, Prime JE et al. Comparative proteomic analysis using samples obtained with laser microdissection and saturation dye labelling. Proteomics5(15), 3851–3858 (2005).
   PubMedGoogle Scholar
• Zabel C, Chamrad DC, Priller J et al. Alterations in the mouse and human proteome caused by Huntington’s disease. Mol. Cell. Proteomics1(5), 366–375 (2002).
   PubMed Web of Science ®Google Scholar
• Zabel C, Sagi D, Kaindl AM et al. Comparative proteomics in neurodegenerative and non-neurodegenerative diseases suggest nodal point proteins in regulatory networking. J. Proteome Res.5(8), 1948–1958 (2006).
   PubMed Web of Science ®Google Scholar
• Patterson SD, Aebersold RH. Proteomics: the first decade and beyond. Nat. Genet.33(Suppl.), 311–323 (2003).
   PubMed Web of Science ®Google Scholar
• Smalheiser NR. Informatics and hypothesis-driven research. EMBO Rep.3(8), 702 (2002).
   PubMedGoogle Scholar
• Allen JF. In silico veritas. Data-mining and automated discovery: the truth is in there. EMBO Rep.2(7), 542–544 (2001).
   PubMedGoogle Scholar
• Moreira JM, Ohlsson G, Rank FE, Celis JE. Down-regulation of the tumor suppressor protein 14-3-3σ is a sporadic event in cancer of the breast. Mol. Cell. Proteomics4(4), 555–569 (2005).
   PubMed Web of Science ®Google Scholar
• Ohlsson G, Moreira JM, Gromov P, Sauter G, Celis JE. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol. Cell. Proteomics4(4), 570–581 (2005).
   PubMed Web of Science ®Google Scholar
• McGregor E, Dunn MJ. Proteomics of the heart: unraveling disease. Circ. Res.98(3), 309–321 (2006).
   PubMed Web of Science ®Google Scholar
• McGregor E, Dunn MJ. Proteomics of heart disease. Hum. Mol. Genet.12(Spec. 2), R135–R144 (2003).
   PubMedGoogle Scholar
• Bauer JW, Baechler EC, Petri M et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med.3(12), E491 (2006).
   PubMed Web of Science ®Google Scholar
• Grant JE, Hu J, Liu T, Jain MR, Elkabes S, Li H. Post-translational modifications in the rat lumbar spinal cord in experimental autoimmune encephalomyelitis. J. Proteome Res.6(7), 2786–2791 (2007).
   PubMedGoogle Scholar
• Schulz M, Dotzlaw H, Mikkat S, Eggert M, Neeck G. Proteomic analysis of peripheral blood mononuclear cells: selective protein processing observed in patients with rheumatoid arthritis. J. Proteome Res.6(9), 3752–3759 (2007).
   PubMed Web of Science ®Google Scholar
• No authors listed. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell72(6), 971–983 (1993).
   PubMed Web of Science ®Google Scholar
• Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet368(9533), 387–403 (2006).
   PubMed Web of Science ®Google Scholar
• Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet363(9423), 1783–1793 (2004).
   PubMed Web of Science ®Google Scholar
• Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington’s disease. J. Neuropathol. Exp. Neurol.44(6), 559–577 (1985).
   PubMed Web of Science ®Google Scholar
• Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer’s disease brain is downregulated at the mRNA and dysregulated at the protein level. J. Neural Transm. Suppl.57, 161–177 (1999).
   PubMedGoogle Scholar
• Krapfenbauer K, Berger M, Lubec G, Fountoulakis M. Changes in the brain protein levels following administration of kainic acid. Electrophoresis22(10), 2086–2091 (2001).
   PubMedGoogle Scholar
• Tilleman K, Van den Haute C, Geerts H, van Leuven F, Esmans EL, Moens L. Proteomics analysis of the neurodegeneration in the brain of tau transgenic mice. Proteomics2(6), 656–665 (2002).
   PubMed Web of Science ®Google Scholar
• Bajo M, Fruehauf J, Kim SH, Fountoulakis M, Lubec G. Proteomic evaluation of intermediary metabolism enzyme proteins in fetal Down’s syndrome cerebral cortex. Proteomics2(11), 1539–1546 (2002).
   PubMedGoogle Scholar
• Newman SF, Sultana R, Perluigi M et al. An increase in S-glutathionylated proteins in the Alzheimer’s disease inferior parietal lobule, a proteomics approach. J. Neurosci. Res.85(7), 1506–1514 (2007).
   PubMedGoogle Scholar
• Hartl D, Irmler M, Römer I et al. Transcriptome and proteome analysis of early embryonic mouse brain development. Proteomics8(6),1257–1265 (2008).
   PubMedGoogle Scholar
• Challapalli KK, Zabel C, Schuchhardt J, Kaindl AM, Klose J, Herzel H. High reproducibility of large-gel two-dimensional electrophoresis. Electrophoresis25(17), 3040–3047 (2004).
   PubMed Web of Science ®Google Scholar
• Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol.17(10), 994–999 (1999).
   PubMed Web of Science ®Google Scholar
• Tannu NS, Hemby SE. Methods for proteomics in neuroscience. Prog. Brain Res.158, 41–82 (2006).
   PubMed Web of Science ®Google Scholar
• Mangiarini L, Sathasivam K, Seller M et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell87(3), 493–506 (1996).
   PubMed Web of Science ®Google Scholar
• Berth M, Moser FM, Kolbe M, Bernhardt J. The state of the art in the analysis of two-dimensional gel electrophoresis images. Appl. Microbiol. Biotechnol.76(6), 1223–1243 (2007).
   PubMed Web of Science ®Google Scholar
• Hoerndli F, David DC, Gotz J. Functional Genomics meets neurodegenerative disorders. Part II: application and data integration. Prog. Neurobiol.76(3), 169–188 (2005).
   PubMed Web of Science ®Google Scholar
• Limviphuvadh V, Tanaka S, Goto S, Ueda K, Kanehisa M. The commonality of protein interaction networks determined in neurodegenerative disorders (NDDs). Bioinformatics23(16), 2129–2138 (2007).
   PubMedGoogle Scholar
• Powers WJ, Videen TO, Markham J et al. Selective defect of in vivo glycolysis in early Huntington’s disease striatum. Proc. Natl Acad. Sci. USA104(8), 2945–2949 (2007).
   PubMed Web of Science ®Google Scholar
• Atamna H, Frey WH II. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease. Mitochondrion7(5), 297–310 (2007).
   PubMed Web of Science ®Google Scholar
• Huang C, Tang C, Feigin A et al. Changes in network activity with the progression of Parkinson’s disease. Brain130(Pt 7), 1834–1846 (2007).
   PubMed Web of Science ®Google Scholar
• Browne SE, Yang L, DiMauro JP, Fuller SW, Licata SC, Beal MF. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiol. Dis.22(3), 599–610 (2006).
   PubMed Web of Science ®Google Scholar
• Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell127(1), 59–69 (2006).
   PubMed Web of Science ®Google Scholar
• McGill JK, Beal MF. PGC-1α, a new therapeutic target in Huntington’s disease? Cell127(3), 465–468 (2006).
   PubMedGoogle Scholar
• St-Pierre J, Drori S, Uldry M et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell127(2), 397–408 (2006).
   PubMed Web of Science ®Google Scholar
• Cowan CM, Raymond LA. Selective neuronal degeneration in Huntington’s disease. Curr. Top. Dev. Biol.75, 25–71 (2006).
   PubMed Web of Science ®Google Scholar
• Dickson DW. Linking selective vulnerability to cell death mechanisms in Parkinson’s disease. Am. J. Pathol.170(1), 16–19 (2007).
   PubMedGoogle Scholar
• Zhu JH, Horbinski C, Guo F, Watkins S, Uchiyama Y, Chu CT. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am. J. Pathol.170(1), 75–86 (2007).
   PubMed Web of Science ®Google Scholar
• Zoghbi HY, Botas J. Mouse and fly models of neurodegeneration. Trends Genet.18(9), 463–471 (2002).
   PubMed Web of Science ®Google Scholar
• Mao L, Zabel C, Herrmann M et al. Proteomic shifts in embryonic stem cells with gene dose modifications suggest the presence of balancer proteins in protein regulatory networks. PLoS ONE2(11), E1218 (2007).
   PubMed Web of Science ®Google Scholar
• Zabel C, Klose J. Influence of Huntington’s disease on the human and mouse proteome. Int. Rev. Neurobiol.61, 241–283 (2004).
   PubMedGoogle Scholar